Intratumoral Administration of Dendritic Cells Overexpressing CCL21 Generates Systemic Antitumor Responses and Confers Tumor Immunity

Clinical Cancer Research

Volumn 10, Issue 8, 2004, Pages 2891-2901

  Yang, Seok Chul ^a,b   Hillinger, Sven ^a,b   Riedl, Karen ^a,b   Zhang, Ling ^a,b   Zhu, Li ^a,c   Huang, Min ^a,c   Atianzar, Kimberly ^a   Kuo, Brian Y ^a   Gardner, Brian ^a,c   Batra, Raj K ^a,c   Strieter, Robert M ^a,b   Dubinett, Steven M ^a,b,c   Sharma, Sherven ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Molecular Gene Medicine Laboratory   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE; CHEMOKINE RECEPTOR CXCR4; GAMMA INTERFERON; GLYCOPROTEIN P 15095; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 2 RECEPTOR; PROSTAGLANDIN E2; SECONDARY LYMPHOID TISSUE CHEMOKINE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CARCINOGENESIS; CONTROLLED STUDY; CONVALESCENCE; DENDRITIC CELL; LUNG CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY;

ADENOVIRIDAE; ANIMALS; ANTIGENS, CD3; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CHEMOKINES, CC; CYTOKINES; DENDRITIC CELLS; DINOPROSTONE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBROBLASTS; GENETIC VECTORS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; IMMUNOENZYME TECHNIQUES; IMMUNOTHERAPY; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; T-LYMPHOCYTES; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA;

EID: 11144358381     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0380     Document Type: Article

References (83)

1. Huang AYC, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994;264:961-5.
2. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991;9:271-96.
3. Gabrilovich DI, Chen HL, Girgis KR, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996;2:1096-1103.
4. Sharma S, Stolina M, Yang SC, et al. Tumor Cyclooxygenase 2-dependent suppression of dendritic cell function. Clin Cancer Res 2003;9:961-8.
5. Kobie JJ, Wu RS, Kurt RA, et al. Transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines. Cancer Res 2003;63:1860-4.
6. Miller PW, Sharma S, Stolina M, et al. Dendritic cells augment granulocyte-macrophage colony-stimulating factor (GMCSF)/herpes simplex virus thymidine kinase-mediated gene therapy of lung cancer. Cancer Gene Ther 1998;5:380-9.
7. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328-32.
8. Ribas A, Butterfield L, McBride W, et al. Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells. Cancer Res 1997;57:2865-9.
9. Sharma S, Miller P, Stolina M, et al. Multi-component gene therapy vaccines for lung cancer: effective eradication of established murine tumors in vivo with interleukin 7/herpes simplex thymidine kinase-transduced autologous tumor and ex vivo-activated dendritic cells. Gene Ther 1997;4:1361-70.
10. Zitvogel L, Mayordomo JI, Tjandrawan T, et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 1996;183:87-97.
11. Dallal RM, Lotze MT. The dendritic cell and human cancer vaccines. Curr Opin Immunol 2000;12:583-8.
12. Banchereau J, Palucka AK, Dhodapkar M, et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 2001;61:6451-8.
13. Banchereau J, Schuler-Thurner B, Palucka AK, Schuler G. Dendritic cells as vectors for therapy. Cell 2001;106:271-4.
14. Schuler G, Schuler-Thurner B, Steinman RM. The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 2003;15:138-47.
15. Boczkowski D, Nair SK, Snyder D, Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1996;184:465-72.
16. Celluzzi, CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD Jr. 1996. Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity. J Exp Med 183:283-7.
17. Mayordomo JI, Zorina T, Storkus WJ, et al. Bone marrow-derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumor immunity. Nat Med 1995;1:1297-1302.
18. Netter E, Troufleau P, Stines J. Ductal carcinoma in situ of the breast: role of imaging. J Radiol 1998;79:651-8.
19. Celluzzi C, Falo LJ. Cutting edge: Physical interaction between dendritic cells and tumor cells result in an immunogen that induces protective and therapeutic tumor rejection. J Immunol 1998;160:3081-5.
20. Gong J, Chen D, Kashiwaba M, Kufe D. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med 1997;3:558-61.
21. Parkhurst MR, DePan C, Riley JP, Rosenberg SA, Shu S. Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules. J Immunol 2003;170:5317-25.
22. Toes R, van der Voort E, Schoenberger S, et al. Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells. J Immunol 1998;160:4449-56.
23. Fields RC, Shimizu K, Mule JJ. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci USA 1998;95:9482-7.
24. Toes RE, Hoeben RC, van der Voort EI, et al. Protective anti-tumor immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T lymphocyte epitopes in a string-of-beads fashion. Proc Natl Acad Sci USA 1997;94:14660-5.
25. Kirk CJ, Hartigan-O'Connor D, Nickoloff BJ, et al. T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy. Cancer Res 2001;61:2062-70.
26. Miller PW, Sharma S, Stolina M, et al. Intratumoral administration of adenoviral interleukin 7 gene-modified dendritic cells augments specific antitumor immunity and achieves tumor eradication. Hum Gene Ther 2000;11:53-65.
27. Cyster JG. Chemokines and the homing of dendritic cells to the T cell areas of lymphoid organs. J Exp Med 1999;189:447-50.
28. Ogata M, Zhang Y, Wang Y, et al. Chemotactic response toward chemokines and its regulation by transforming growth factor-betal of murine bone marrow hematopoietic progenitor cell-derived different subset of dendritic cells. Blood 1999;93:3225-32.
29. Chan VW, Kothakota S, Rohan MC, et al. Secondary lymphoid-tissue chemokine (SLC) is chemotactic for mature dendritic cells. Blood 1999;93:3610-16.
30. Hedrick JA, Zlotnik A. Identification and characterization of a novel beta chemokine containing six conserved cysteines. J Immunol 1997;159:1589-93.
31. Hromas, R, Kim CH, Klemsz M, et al. Isolation and characterization of Exodus-2, a novel CC chemokine with a unique 37-amino acid carboxyl-terminal extension. J Immunol 1997;159:2554-8.
32. Nagira M, Imai T, Hieshima K, et al. Molecular cloning of a novel human CC chemokine secondary lymphoid-tissue chemokine that is a potent chemoattractant for lymphocytes and mapped to chromosome 9p13. J Biol Chem 1997;272:19518-24.
33. Tanabe S, Lu Z, Luo Y, et al. Identification of a new mouse beta-chemokine, thymus-derived chemotactic agent 4, with activity on T lymphocytes and mesangial cells. J Immunol 1997;159:5671-9.
34. Willimann K, Legler DF, Loetscher M, et al. The chemokine SLC is expressed in T cell areas of lymph nodes and mucosal lymphoid tissues and attracts activated T cells via CCR7. Eur J Immunol 1998;28:2025-34.
35. Kellermann SA, Hudak S, Oldham ER, Liu YJ, McEvoy LM. The CC chemokine receptor-7 ligands 6Ckine and macrophage inflammatory protein-3 beta are potent chemoattractants for in vitro- and in vivo-derived dendritic cells. J Immunol 1999;162:3859-64.
36. Sallusto F, Schaerli P, Loetscher P, et al. Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation. Eur J Immunol 1998;28:2760-9.
37. Sozzani S, Allavena P, D'Amico G, et al. Differential regulation of chemokine receptors during dendritic cell maturation: a model for their trafficking properties. J Immunol 1998;161:1083-6.
38. Dieu MC, Vanbervliet B, Vicari A, et al. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med 1998;188:373-86.
39. Sharma S, Stolina M, Luo J, et al. Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. J Immunol 2000;164:4558-63.
40. Soto H, Wang W, Strieter RM, et al. The CC chemokine 6Ckine binds the CXC chemokine receptor CXCR3. Proc Natl Acad Sci USA 1998;95:8205-10.
41. Vicari AP, Yahia SA, Chemin K, Mueller A, Zlotnik A, Caux C. Antitumor effects of the mouse chemokine 6ckine/slc through angiostatic and immunological mechanisms. J Immunol 2000;165:1992-2000.
42. Arenberg DA, Zlotnick A, Strom SRB, Burdick MD, Strieter RM. The murine CC chemokine, 6Ckine, inhibits tumor growth and angiogenesis in a human lung cancer SCID mouse model. Cancer Immunol Immunother 2000;49:587-92.
43. Belperio JA, Keane MP, Burdick MD, et al. Critical role for CXCR3 chemokine biology in the pathogenesis of bronchiolitis obliterans syndrome. J Immunol 2002;169:1037-49.
44. Spitalny GL, Havell EA. Monoclonal antibody to murine gamma interferon inhibits lymphokine-induced antiviral and macrophage tumoricidal activities. J Exp Med 1984;159:1560-5.
45. Yuhas J, Toya R, Wagner E. Specific and nonspecific stimulation of resistence to the growth and metastasis of the line 1 lung carcinoma. Cancer Res 1975;35:242-4.
46. Inaba K, Inaba M, Romani N, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophages colony-stimulated factor. J Exp Med 1992;176:1693-1702.
47. Arthur J, Butterfield L, Roth M, et al. A comparison of gene transfer methods in human dendritic cells. Cancer Gene Ther 1997;4:17-25.
48. Huang, M, Stolina M, Sharma S, et al. 1998. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res. 58:1208-16.
49. Yang Y, Nunes FA, Berencsi K, Furth EE, Gönczöl E, Wilson JM. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994;91:4407-11.
50. Tannenbaum CS, Tubbs R, Armstrong D, Finke JH, Bukowski RM, Hamilton TA. The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. J Immunol 1998;161:927-32.
51. Qin Z, Noffz G, Mohaupt M, Blankenstein T. Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocyte-macrophage colony-stimulating factor gene-modified tumor cells. J Immunol 1997;159:770-6.
52. Gabrilovich DI, Corak J, Ciernik IF, Kavanaugh D, Carbone DP. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res 1997;3:483-90.
53. Gabrilovich D, Ishida T, Oyama T, et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998;92:4150-66.
54. Dhodapkar MV, Steinman RM. Antigen-bearing immature dendritic cells induce peptide-specific CD8(+) regulatory T cells in vivo in humans. Blood 2002;100:174-7.
55. Rahman, A, Tsai V, Goudreau A, et al. 2001. Specific depletion of human anti-adenovirus antibodies facilitates transduction in an in vivo model for systemic gene therapy. Mol Ther 3:768-78.
56. Dubinett SM, Batra RK, Miller PW, Sharma S. Tumor antigens in thoracic malignancy. Am J Respir Cell Mol Biol 2000;22:524-7.
57. Shimizu, T, Berhanu A, Redlinger RE Jr, Watkins S, Lotze MT, Barksdale EM Jr. Interleukin-12 transduced dendritic cells induce regression of established murine neuroblastoma. J Pediatr Surg 2001;36:1285-92.
58. Melero I, Duarte M, Ruiz J, et al. Intratumoral injection of bone-marrow derived dendritic cells engineered to produce interleukin-12 induces complete regression of established murine transplantable colon adenocarcinomas. Gene Ther 1999;6:1779-84.
59. Kirk CJ, Mule JJ. Gene-modified dendritic cells for use in tumor vaccines. Hum Gene Ther 2000;11:797-806.
60. Gambotto A, Tuting T, McVey D, et al. Induction of antitumor immunity by direct intratumoral injection of a recombinant adenovirus vector expressing interleukin-12. Cancer Gene Ther 1999;6:45-53.
61. Nishioka Y, Hirao M, Robbins PD, Lotze MT, Tahara H. Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12. Cancer Res 1999;59:4035-41.
62. Kikuchi T, Moore MA, Crystal RG. Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors. Blood 2000;96:91-9.
63. Akiyama Y, Watanabe M, Maruyama K, Ruscetti FW, Wiltrout RH, Yamaguchi K. Enhancement of antitumor immunity against B16 melanoma tumor using genetically modified dendritic cells to produce cytokines. Gene Ther 2000;7:2113-21.
64. Kirk C, Hartigan-O'Connor D, Mule J. The dynamics of the T-cell antitumor response: chemokine-secreting dendritic cells can prime tumor-reactive t cells extranodally. Cancer Res 2001;61:8794-802.
65. Bellone G, Turletti A, Artusio E, et al. Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients. Am J Pathol 1999;155:537-47.
66. Fajardo LF, Prionas SD, Kwan HH, Kowalski J, Allison AC. Transforming growth factor beta1 induces angiogenesis in vivo with a threshold pattern. Lab Investig 1996;74:600-8.
67. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705-16.
68. Katakura Y, Nakata E, Tabira Y, et al. Decreased tumorigenicity in vivo when transforming growth factor beta treatment causes cancer cell senescence. Biosci Biotechnol Biochem 2003;67:815-21.
69. Stolina M, Sharma S, Lin Y, et al. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol 2000;164:361-70.
70. Hu HM, Urba WJ, Fox BA. Gene-modified tumor vaccine with therapeutic potential shifts tumor- specific T cell response from a type 2 to a type 1 cytokine profile. J Immunol 1998;161:3033-41.
71. Trinchieri G. Interleukin-12: a cytokine at the interface of inflammation and immunity. Adv Immunol 1998;70:83-243.
72. Johnson LL, Sayles P. Interleukin-12, dendritic cells and the initiation of of host -protective mechanisms against Toxoplasma gondii. J Exp Med 1997;186:1799-802.
73. Ma X, Amezaga A, Gri G, Gerosa F, Trichieri G. Immunomodulatory functions and molecular regulations of IL-12. Chem Immunol 1997;68:1-22.
74. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 1995;87:581-6.
75. Banchereau, J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-52.
76. Loetscher M, Gerber B, Loetscher P, et al. Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. J Exp Med 1996;184:963-9.
77. Brunda MJ, Luistro L, Warrier RR, et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 1993;178:1223-30.
78. Luster AD, Leder P. IP-10, a CXC chemokine, elicits a potent thymus- dependent anti-tumor response in vivo. J Exp Med 1993;178:1057-65.
79. Arenberg DA, Kunkel SL, Polverini PJ, et al. Strieter. Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J Exp Med 1996;184:981-92.
80. Sgadari C, Farber JM, Angiolillo AL, et al. Mig, the monokine induced by interferon-gamma, promotes tumor necrosis in vivo. Blood 1997;89:2635-43.
81. Strieter RM, Kunkel SL, Arenberg DA, Burdick MD, Polverini PJ. Interferon gamma-inducible protein 10 (IP-10), a member of the C-X-C chemokine family, is an inhibitor of angiogenesis. Biochem Biophys Res Commun 1995;210:51-7.
82. Farber JM. Mig and IP-10: CXC chemokines that target lymphocytes. J Leukoc Biol 1997;61:246-57.
83. Sharma S, Yang SC, Hillinger S, et al. SLC/CCL21-mediated anti-tumor responses require IFNgamma, MIG/CXCL9 and IP-10/CXCL10. Mol Cancer 2003;2:22-8.